Search

Displaying results 3081 - 3090 of 8698 in total
  1. Drug

    Guanidine

    go.drugbank.com/drugs/DB00536
    Approved

    A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism.

  2. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    FDA approved on May 19, 2009.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Bromelains

    go.drugbank.com/drugs/DB13281
    ApprovedInvestigational

    Bromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase, escharase, and several proteas...

    Mixtures: Alka-pan TabletsCategories: Preparations for Treatment of Wounds and Ulcers
  5. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

  7. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  8. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1. … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness. … an action potential.

    Categories: Neonatal Fc Receptor Blocker
  10. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    While considered safe for use, extensive usage may result in aluminum accumulation. … Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics.